[C-283 in treatment of peritoneal and pleural effusions in patients with ovarian carcinoma].
D000166:Acridines / Q000009:adverse effects / Q000627:therapeutic use*; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D004361:Drug Tolerance; D005260:Female; D006465:Hemoperitoneum / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000150:complications / Q000188:drug therapy*; D010996:Pleural Effusion / Q000187:drug effects*; D011437:Propylamines / Q000009:adverse effects / Q000627:therapeutic use; D012313:RNA / Q000096:biosynthesis
D000166:Acridines; D000970:Antineoplastic Agents; D011437:Propylamines; D012313:RNA
Leczenie zwiakiem C-283 wysieków otrzewnych i opłucnowych u chorych na raka jajników.